and Media

News Releases

Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2018. The event is scheduled to take place on Tuesday, January 9, at 7 a.m. PT (10 a.m. ET) and will be simultaneously webcast.

Portola will provide clinical, regulatory and manufacturing updates on the Company’s first FDA-approved product, betrixaban, and its two investigational hematologic compounds – the anticoagulant reversal agent andexanet alfa and the oral, dual Syk/JAK kinase inhibitor cerdulatinib.

Webcast Details
To access the live investor webcast on Tuesday, January 9 at 7 a.m. PT (10 a.m. ET), go to the Investor Relations section of the company’s website at A replay will be available for 30 days.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma. 

Investor Contact:
Cara Miller
Portola Pharmaceuticals

Media Contact:
Patrick Ryan
W2O Group

Primary Logo

Portola Pharmaceuticals, Inc.